CN115279340A - 利用粉末鼻内肾上腺素的治疗 - Google Patents

利用粉末鼻内肾上腺素的治疗 Download PDF

Info

Publication number
CN115279340A
CN115279340A CN202180020993.7A CN202180020993A CN115279340A CN 115279340 A CN115279340 A CN 115279340A CN 202180020993 A CN202180020993 A CN 202180020993A CN 115279340 A CN115279340 A CN 115279340A
Authority
CN
China
Prior art keywords
epinephrine
particles
pharmaceutical composition
type
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020993.7A
Other languages
English (en)
Chinese (zh)
Inventor
加利亚·铁姆辛-克雷兹
帕维尔·卡兹丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nasus Pharma Ltd
Original Assignee
Nasus Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasus Pharma Ltd filed Critical Nasus Pharma Ltd
Publication of CN115279340A publication Critical patent/CN115279340A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
CN202180020993.7A 2020-03-16 2021-03-16 利用粉末鼻内肾上腺素的治疗 Pending CN115279340A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US62/989,913 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
US17/135,528 2020-12-28
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
CN115279340A true CN115279340A (zh) 2022-11-01

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020993.7A Pending CN115279340A (zh) 2020-03-16 2021-03-16 利用粉末鼻内肾上腺素的治疗

Country Status (13)

Country Link
US (2) US11400045B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121005A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517532A (cg-RX-API-DMAC7.html)
KR (1) KR20220154709A (cg-RX-API-DMAC7.html)
CN (1) CN115279340A (cg-RX-API-DMAC7.html)
AR (1) AR121593A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021239084A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018440A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175130A1 (cg-RX-API-DMAC7.html)
IL (1) IL296268A (cg-RX-API-DMAC7.html)
MX (1) MX2022011464A (cg-RX-API-DMAC7.html)
TW (1) TW202200119A (cg-RX-API-DMAC7.html)
WO (1) WO2021186437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AU2023322235A1 (en) * 2022-08-11 2025-03-13 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20260016535A (ko) * 2023-05-31 2026-02-03 오렉쏘 에이비 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물
US20260108465A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166219A (zh) * 2010-05-25 2011-08-31 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
CN110505873A (zh) * 2018-02-06 2019-11-26 爱奇司治疗公司 鼻内肾上腺素制剂及治疗疾病的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940006601A (ko) 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ATE289825T1 (de) 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
GB2367756B (en) 2000-10-12 2003-01-08 Bespak Plc Dispensing apparatus
GB2380410B (en) 2001-10-05 2003-11-19 Alchemy Healthcare Ltd Apparatus for the nasal or oral delivery of a medicament
GB2384190A (en) 2002-01-22 2003-07-23 Bespak Plc Dispensing device for a powdered product
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
GB0524194D0 (en) 2005-11-28 2006-01-04 Univ Aston Respirable powders
EP1960022A1 (en) 2005-11-29 2008-08-27 Alza Corporation Nasal delivery device for the delivery of a substance to the olfactory region
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
WO2009050726A2 (en) 2007-05-28 2009-04-23 Panacea Biotec Limited Compositions and methods for improved delivery of bupropion
RU2491067C2 (ru) 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014134070A1 (en) 2013-02-26 2014-09-04 Baxter International Inc. Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
CN104274426A (zh) 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
CN105979999B (zh) 2013-12-11 2021-03-12 株式会社Jms 阳型连接器
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
KR20200125632A (ko) * 2018-02-26 2020-11-04 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 분말 제제, 카트리지 및 디바이스
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166219A (zh) * 2010-05-25 2011-08-31 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
CN110505873A (zh) * 2018-02-06 2019-11-26 爱奇司治疗公司 鼻内肾上腺素制剂及治疗疾病的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
国家药典委员会: "《中华人民共和国药典 2015年版 四部》", 31 July 2015, 中国医药科技出版社, pages: 9 - 10 *
姚静: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社, pages: 122 - 124 *
程刚: "《生物药剂学 第5版》", 31 December 2019, 中国医药科技出版社, pages: 79 - 81 *

Also Published As

Publication number Publication date
AU2021239084A1 (en) 2022-10-13
US12678402B2 (en) 2026-07-14
US11400045B2 (en) 2022-08-02
BR112022018440A2 (pt) 2022-11-01
US20230105615A1 (en) 2023-04-06
WO2021186437A1 (en) 2021-09-23
MX2022011464A (es) 2022-11-14
EP4121005A1 (en) 2023-01-25
TW202200119A (zh) 2022-01-01
AR121593A1 (es) 2022-06-22
CA3175130A1 (en) 2021-09-23
IL296268A (en) 2022-11-01
KR20220154709A (ko) 2022-11-22
JP2026094260A (ja) 2026-06-09
US20210283050A1 (en) 2021-09-16
JP2023517532A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
US11400045B2 (en) Treatment with powdered intranasal epinephrine
CN110996912A (zh) 用于鼻内递送的干粉组合物
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
KR20030038541A (ko) 안정한 약물 전달용 금속 이온-지질 분말 약제학적 조성물및 그것의 사용 방법
EP2229148B1 (en) Process for preparing a particulate and crystalline drug substance
CN105101955A (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
CN118045069A (zh) 利用三流体喷嘴制备可吸入复合颗粒的方法
US20250387327A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US20140377365A1 (en) Sustained-release formulation of rotigotine
KR20050105490A (ko) 경폐 투여용 서방성 제제학적 조성물
Sallam Recent advances in the formulation development of inhalational dosage forms
BR112020023812A2 (pt) sal de cisteamina inovador para a preparação de partículas altamente respiráveis
CN107847482A (zh) 喷雾器用组合物
KR19990021931A (ko) 미세구형 전분의 항편두통 조성물
CN121648088A (zh) 一种缓释的西维来司他或其盐的药物组合物及其制备方法
CN121648089A (zh) 一种缓释的西维来司他组合物及其制备方法
TWI597072B (zh) 包覆脂肪酸的β-致效劑之結晶微粒
CN114796182A (zh) 益母草碱在用于制备防治间歇性跛行的药物中的应用
CN121568681A (zh) 包含肾上腺素能受体调节剂的喷雾干燥组合物
Auriemma et al. Gentamicin and particle engineering: from an old molecule to innovative drug delivery systems
HK1218867B (en) Respiratory delivery of active agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20221101